Physician

Shailja Roy, MD

According to 2025 Medicare claims, Shailja Roy, MD (NPI: 1508898594) practices hematology/oncology in the Vineland, NJ market, with the plurality of this provider's patient population coming from Cumberland, NJ. This provider's primary affiliated billing organization is SOUTHERN ONCOLOGY HEMATOLOGY ASSOC (NPI: 1144211087; TIN: 222182145) and primary practice location at 08360-7059.

Roy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 617 traditional Medicare patients, billed 114,596 HCPCS/CPT codes, and received $1,398,004 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,561 prescription claims across 278 beneficiaries totaling $6,096,356 in drug costs, led by Ibrance (Palbociclib). 2019 DME data shows 11 claims. Open Payments data shows 95 records totaling $1,649. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,894,472 and ending at $1,398,004. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $932,310 to $6,096,356. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	956	174,838	$1,894,472
2016	879	176,672	$1,706,332
2017	769	156,400	$2,340,136
2018	685	184,091	$2,666,981
2019	660	187,206	$1,763,875
2020	602	175,284	$1,639,861
2021	646	221,846	$2,057,938
2022	574	136,832	$1,630,278
2023	582	166,472	$1,925,546
2024	617	114,596	$1,398,004

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	142	722	$932,310
2016	134	674	$985,294
2017	166	723	$1,266,118
2018	174	903	$1,915,932
2019	194	1,144	$3,015,899
2020	202	1,281	$4,100,562
2021	233	1,177	$3,413,992
2022	249	1,151	$4,268,626
2023	260	1,421	$5,488,151
2024	278	1,561	$6,096,356

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	16	$1,879
2016	N/R	37	$1,598
2017	N/R	85	$9,601
2018	N/R	N/R	N/R
2019	N/R	11	$207
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	79	81	$149
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	229	444	$105
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	281	453	$72
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	92	148	$67
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	292	756	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	81	2,268	$1,248,049
Keytruda	Pembrolizumab	53	1,113	$597,694
Imbruvica	Ibrutinib	24	672	$365,260
Lenvima	Lenvatinib Mesylate	15	450	$360,044
Lenalidomide	Lenalidomide	20	560	$268,604

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	95	$1,649	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shailja Roy, MD?

Tedicare shows public-source Medicare data for Shailja Roy, MD (NPI 1508898594), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shailja Roy, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Shailja Roy, MD?

Shailja Roy, MD is linked to SOUTHERN ONCOLOGY HEMATOLOGY ASSOC (billing NPI 1144211087) in the available physician profile data.

Does Shailja Roy, MD have Open Payments data?

Shailja Roy, MD has 95 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.